Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing
Journal of Clinical Microbiology · 2025
DOI: 10.1128/jcm.01079-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Gerardo J Sanchez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Microbiology, KU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Flanders, Belgium. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Anti-Bacterial Agents, Whole Genome Sequencing, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Determination of antimicrobial resistance (AMR) in pneumococcal isolates is important for surveillance purposes and in a clinical context. Antimicrobial susceptibility testing (AST) of pneumococci is complicated by the need for exact minimal inhibitory concentrations (MICs) of beta-lactam antibiotics. Two next-generation sequencing (NGS) analysis tools have implemented the prediction of AMR in their analysis workflow, including the prediction of MICs: Pathogenwatch ( https://pathogen.watch/ ) and AREScloud (OpGen). The performance of these tools in comparison to phenotypic AST following EUCAST guidelines is unknown. A total of 538 Streptococcus pneumoniae isolates were used to compare both tools with phenotypic AST for penicillin, amoxicillin, cefotaxime/ceftriaxone, erythromycin, trimethoprim-sulfamethoxazole, and tetracycline. Disk diffusion was performed for all isolates, and broth microdilution was performed for isolates with reduced beta-lactam susceptibility. Demultiplexed FASTQ files from Illumina sequencing, covering the whole genome of pneumococci, were used as input for the NGS tools. Categorical agreement (CA), major error (ME), and very major error (VME) rates were calculated. For beta-lactam antibiotics, CA was high (>94%) associated with none or only one ME and VME (93% for predictions by AREScloud, while for Pathogenwatch, this ranged around 88%. For trimethoprim-sulfamethoxazole, CA was for both tools
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Microbiology, KU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Flanders, Belgium.
- Department of Laboratory Medicine, National Reference Centre for Invasive Pneumococci, University Hospitals Leuven, Leuven, Flanders, Belgium.
- Ares Genetics, OpGen, Vienna, Austria.
- Day Zero Diagnostics Inc., Watertown, Massachusetts, USA.
ORCID-Profile: Gerardo J Sanchez, Stefanie Desmet
Zitieren
APA
Sanchez, G. J., Cuypers, L., Laenen, L., Májek, P., Lagrou, K., & Desmet, S. (2025). Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01079-24
Vancouver
Sanchez GJ, Cuypers L, Laenen L, Májek P, Lagrou K, Desmet S. Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.01079-24
BibTeX
@article{Sanchez2025,
author = {Sanchez, Gerardo J and Cuypers, Lize and Laenen, Lies and Májek, Peter and Lagrou, Katrien and Desmet, Stefanie},
title = {Prediction of antimicrobial susceptibility of pneumococci based on whole-genome sequencing data: a direct comparison of two genomic tools to conventional antimicrobial susceptibility testing},
journal = {Journal of Clinical Microbiology},
year = {2025},
doi = {10.1128/jcm.01079-24}
}
EUVIMED